CBD is treatment for many ailments

FDA Attempts to Regulate CBD as Investigational New Drug

In cbd, legal by Josh Whitaker2 Comments

The Food & Drug Administration (FDA) is continuing its attempts to label CBDs as an Investigational New Drug (IND) and therefore, non-compliant as a dietary supplement. The very targeting of CBDs by the FDA is further proof of their lack of insight regarding the medical potential of CBDs.

The first step in understanding how outrageous the FDA’s recent attacks on CBDs are is to know the properties and function of cannabidiols. Yes, cannabidiols is the proper term because there are at least seven distinct molecular variants of cannabidiols. CBDs (cannabidiols) are non-psychoactive compounds found in hemp oil extract with a proven history of naturally treating serious health conditions, such as epilepsy, Parkinson’s, and others. (U.S. News)

However, in the face of CBDs’ proven medical efficacy, the FDA still makes this claim on its own website,

“Based on available evidence, FDA has concluded that cannabidiol products are excluded from the dietary supplement definition…” (FDA)

To be clear, no law from Congress has been passed banning the creation, distribution, or usage of CBDs. The dilemma facing the FDA is that CBDs are more effective than pharmaceutical drugs in treating these conditions. Drug companies are now investigating CBDs for approval by the FDA for medicinal application. This well-intended pursuit is allowing the FDA to formally label CBDs as an Investigational New Drug (IND).

Because CBDs are now being investigated as a new drug, the FDA sees this opportunity for regulating CBDs as non-compliant dietary supplements. Per the FDA’s website,

“FDA has concluded that cannabidiol products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act. Under that provision, if a substance (such as cannabidiol) has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.”

Translation: if the FDA is now classifying CBDs as a drug, CBDs cannot be included as a dietary ingredient simply because drug companies are curious of their healing potential. As judge and jury of its own regulation “laws”, the FDA is attempting to regulate CBDs into either non-existence or Big Pharma exclusive control. Some CBD distributors have fallen victim to the FDA’s scrutiny as several companies received warning letters last year. (Nutritional Outlook) The ludicrousness of the FDA’s logic shows an intent to monopolize natural food ingredients, including CBDs. We do support regulating and condemning distributors who use inaccurate label claims or even fraudulent claims of including CBDs when none is present. (Forbes.com) This is why we highly recommend purchasing CBDs from only reputable distributors. 

The FDA’s systemic attack of fraudulent CBD distributors followed by distributors with inaccurate medical claim labels is setting up for a final front: a regulation-heavy bullying of established and reputable CBDs distributors. The FDA is attempting to control what nature freely gives, a right and access to enjoy the healing benefits of cannabidiols. Imagine a world that could be free of epilepsy and other debilitating diseases. If the FDA has their way, that world may never exist.




Leave a Comment